Unicycive Therapeutics, Inc.

NASDAQ:UNCY

0.43 (USD) • At close October 21, 2024
Bedrijfsnaam Unicycive Therapeutics, Inc.
Symbool UNCY
Munteenheid USD
Prijs 0.435
Beurswaarde 41,016,640
Dividendpercentage 0%
52-weken bereik 0.202 - 1.818
Industrie Biotechnology
Sector Healthcare
CEO Dr. Shalabh K. Gupta M.D., MPA
Website https://www.unicycive.com

An error occurred while fetching data.

Over Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based

Vergelijkbare Aandelen

NeuroBo Pharmaceuticals, Inc. logo

NeuroBo Pharmaceuticals, Inc.

NRBO

2.92 USD

Rockwell Medical, Inc. logo

Rockwell Medical, Inc.

RMTI

3.475 USD

Cyclacel Pharmaceuticals, Inc. logo

Cyclacel Pharmaceuticals, Inc.

CYCCP

11.81 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)